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A Randomized Clinical Trial
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IMPORTANCE Antipsychotic medications for the treatment of schizophrenia have limitations,
and new treatments are needed. A prior pilot investigation suggested that adjunctive sodium
nitroprusside (SNP) administered intravenously had rapid efficacy in the treatment of
patients with schizophrenia.
OBJECTIVE To determine the efficacy and tolerability of intravenous SNP infused at a rate
of 0.5 μg/kg/min for 4 hours in patients with schizophrenia with some degree of treatment
resistance.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind acute treatment
study using a sequential parallel comparison design conducted in two 2-week phases at 4
academic medical centers beginning May 20, 2015, and ending March 31, 2017. Participants
were adults 18 to 65 years of age with a diagnosis of schizophrenia as confirmed by the
Structured Clinical Interview for DSM-IV, taking antipsychotic medication for at least 8 weeks,
and had at least 1 failed trial of an antipsychotic medication within the past year. A total of
90 participants consented, 60 participants enrolled, and 52 participants were included in the
analyses. A modified intent-to-treat analysis was used.
INTERVENTIONS Participants were randomized in a 1:1:1 ratio to 1 of 3 treatment sequences:
SNP and SNP, placebo and SNP, and placebo and placebo. The SNP and SNP group received
SNP in phase 1 and SNP in phase 2 for the purpose of blinding, but the data from phase 2 were
not included in the results. The placebo and SNP group received placebo in phase 1 and SNP
in phase 2. If there was no response to placebo in phase 1, data from phase 2 were included in
the analyses. The placebo and placebo group received placebo in both phases; if there was no
response to placebo in phase 1, data from phase 2 were included in the analyses.
MAIN OUTCOMES AND MEASURES Effectiveness of SNP compared with placebo in improving
Positive and Negative Syndrome Scale (PANSS) total, positive, and negative scores across
each 2-week phase.
RESULTS Fifty-two participants (12 women and 40 men) were included in the study. In the
SNP and SNP group, the mean (SD) age was 47.1 (10.5) years. In the placebo and SNP group,
the mean (SD) age was 45.9 (12.3) years. In the placebo and placebo group, the mean (SD)
age was 40.4 (11.0) years. There were no significant differences between the SNP and
placebo groups at baseline or in change from baseline for PANSS-total (weighted β = –1.04;
z = –0.59; P = .57), PANSS-positive (weighted β = –0.62; z = –0.93; P = .35), or
PANSS-negative (weighted β = –0.12; z = –0.19; P = .85) scores. No significant differences
in safety or tolerability measures were identified.
CONCLUSIONS AND RELEVANCE Although intravenous SNP is well tolerated, it was not an
efficacious adjunctive treatment of positive or negative symptoms of psychosis among
outpatients with schizophrenia with prior history of treatment resistance.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02164981
JAMA Psychiatry. 2019;76(7):691-699. doi:10.1001/jamapsychiatry.2019.0151
Published online March 27, 2019.
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F irst- and second-generation antipsychotic medicationshave proven efficacy in the treatment of the positivesymptoms of schizophrenia.1 However, current antipsy-
chotic medications also have significant limitations, includ-
ing lack of efficacy for negative and cognitive symptoms of
schizophrenia and distressing adverse effects, and reduction
in psychotic symptoms is often quite delayed.2,3 Further-
more, there is a subset of patients who do not fully respond
to multiple trials of antipsychotic medications, including
clozapine.4,5
In an effort to identify more efficacious treatments, a proof-
of-concept clinical trial investigated intravenous sodium ni-
troprusside (SNP).6 Sodium nitroprusside releases nitric ox-
ide (NO), and N-methyl-D-aspartate (NMDA) receptor activation
also produces intracellular NO release through activation of
neuronal NO synthase (nNOS).7 N-methyl-D-aspartate hypo-
function may contribute to the underlying neurobiology of
schizophrenia. Among 20 individuals, Hallak and colleagues6
showed that a single 4-hour infusion of SNP at 0.5 μg/kg/min
resulted in a significant decrease in psychotic symptoms, as
measured by the Brief Psychiatric Rating Scale. A follow-up pla-
cebo-controlled study demonstrated improvement in impair-
ments in cognitive function with SNP treatment in 20 pa-
tients with schizophrenia.8 However, a subsequent study from
a different group failed to show any benefit of SNP either
in reducing psychotic symptoms or in improving spatial
working memory performance among 20 patients with
schizophrenia.9 Clarifying the potential therapeutic effect of
SNP has both clinical and mechanistic importance: if efficacy
could be confirmed, it might point the way to a new class of
interventions, as with ketamine hydrochloride in major
depressive disorder.
We conducted an adequately powered randomized,
double-blind, placebo-controlled, multicenter clinical trial to
characterize the efficacy and safety of a single dose of intra-
venous SNP in treating the positive, negative, and cognitive
symptoms of patients with schizophrenia. We used a sequen-
tial parallel comparison design (SPCD) to increase statistical
power and diminish placebo response.10
Methods
Participants
This study enrolled outpatients at 4 academic medical cen-
ters (Massachusetts General Hospital, University of Massachu-
setts Medical School, New York University, and the Zucker
Hillside Hospital) beginning May 20, 2015, with the final study
visit completed March 31, 2017. The study was approved
by the Institutional Review Boards at each site. Written in-
formed consent was obtained from all participants (the trial
protocol is available in Supplement 1).
We intended to recruit a total of 60 individuals between
the ages of 18 and 65 years with a primary diagnosis of schizo-
phrenia assessed using the Structured Clinical Interview for
DSM-IV. Participants were included if they had a total score
of 70 or more on the Positive and Negative Syndrome Scale
(PANSS), with a score of 4 or more on 2 or more of the follow-
ing PANSS items: delusions, conceptual disorganization, hal-
lucinatory behavior, suspiciousness, and unusual thought
content.11 Participants were also required to have a score of
4 or more on the Clinical Global Impression–Severity. A confir-
mation of both schizophrenia diagnosis and symptom severity
was carried out by an independent, expert clinician remote rater
from Massachusetts General Hospital (H.E.B.). Participants must
have had ongoing antipsychotic medication treatment for at least
8 weeks, with stable dosing for at least 4 weeks. In addition, in
the past year, they must have failed to achieve a clinically
significant reduction in symptoms after treatment for at least
8 weeks with at least 1 antipsychotic medication at a therapeu-
tic dose. Antipsychotic medication treatment history was con-
firmed using the Massachusetts General Hospital Fast Additive
Summary of Treatment. This questionnaire is an efficient, struc-
tured way to capture individuals’ historical treatments across
mood and psychotic disorders, and includes treatment dura-
tion, response, and reason for discontinuation.
Participants were excluded if they had any major medical
illness, symptomatic orthostatic hypotension, treatment with
medications that may interfere with the metabolism or excre-
tion of SNP, medications associated with drug interactions with
SNP, medications that could pose a significant risk to the par-
ticipants’ health, current alcohol or substance use disorders
(except nicotine), were pregnant or breastfeeding, or were at
imminent risk for suicide or injury to self or others. All par-
ticipants underwent a physical examination, routine labora-
tory tests, urine toxicology test, and 12-lead electrocardio-
gram to ensure medical stability. A board-certified psychiatrist
(H.E.B.) was the medical monitor for this study and reviewed
all adverse events and issues related to participant eligibility.
Procedure
Study Design
The study was conducted in 2 phases. A SPCD design was used
for the 4-week randomized, double-blind phases (phase 1 and
phase 2, both lasting 2 weeks). eFigure 1 in Supplement 2 pro-
vides further details of the study design. The SPCD reduces pla-
cebo response rate and sample size requirement.10 Partici-
pants who met eligibility criteria were randomized in a 1:1:1 ratio
Key Points
Question Is adjunctive intravenous sodium nitroprusside an
efficacious and safe treatment for individuals with schizophrenia
who have some degree of treatment resistance?
Findings In this multicenter, randomized double-blind clinical trial
of 52 adults with chronic schizophrenia treated with antipsychotic
medication, no improvement was seen in positive, negative, or
cognitive symptoms after a 4-hour sodium nitroprusside infusion
at 0.5 μg/kg/min; furthermore, there were no differences in
response when stratified by clozapine treatment status. Overall,
the treatment was well tolerated.
Meaning Results of this well-powered clinical trial suggest that
adding intravenous sodium nitroprusside infused at 0.5 μg/kg/min
is not an efficacious treatment for individuals with schizophrenia
with some history of treatment resistance.
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to 1 of 3 treatment sequences as follows: SNP and SNP, pla-
cebo and SNP, and placebo and placebo. Both participants and
clinicians were blinded to treatment. Participants in the SNP
and SNP group received SNP in phase 1 and SNP in phase 2 for
the purpose of blinding, but the data in phase 2 were not in-
cluded in the study results. Patients in the placebo and SNP
group received placebo in phase 1 and received SNP in phase
2. If they did not respond to placebo (ie, >20% reduction on
the PANSS-total) in phase 1, their data in phase 2 were in-
cluded in the analyses. Patients in the placebo and placebo
group received placebo in both phases; if they did not re-
spond to placebo in phase 1, their data from phase 2 were in-
cluded in the analyses. Participants were also stratified by
antipsychotic treatment status: those who were taking cloza-
pine and those who were taking an antipsychotic medication
other than clozapine. The number of patients taking cloza-
pine was restricted to 20. Finally, we used a median split to
stratify participants by negative symptom severity, as mea-
sured by the PANSS-negative symptom subscale.
To monitor safety and tolerability, participants were also
administered the Abnormal Involuntary Movement Scale and
the Systematic Assessment for Treatment Emergent Effects
(SAFTEE) prior to each infusion, after each infusion, and at
follow-up.12,13 Participants also completed the Columbia-
Suicide Severity Rating Scale14 as well as the Measurement and
Treatment Research to Improve Cognition in Schizophrenia15
Consensus Cognitive Battery, and the University of California
San Diego Performance-based Skills Assessment Brief at 3
different time points.16
Treatment
Prior to starting the initial infusion (phase 1), participants un-
derwent 2 screening visits that included assessment of eligi-
bility. Patients were then observed for 28 days, which in-
cluded 2 treatment phases (phase 1 and phase 2) and a final
follow-up visit. In both phases, participants underwent a base-
line visit, including safety assessments, review of concomi-
tant medications, electrocardiogram, and vital sign monitor-
ing. Participants then returned for a second study visit during
which they received an infusion (either SNP or placebo) and
then a follow-up visit 1 week later. All participants completed
a final follow-up study visit at day 28, including safety assess-
ments, PANSS, electrocardiogram, and vital sign monitoring
(eFigure 2 in Supplement 2).
The clinical trials management software generated a ran-
domization identifier for each participant; the identifier was ac-
cessible to the site pharmacy and was used to prepare the cor-
responding infusion treatment. Participants received either SNP
diluted with dextrose, 5%, infused at a rate of 0.5 μg/kg/min for
4 hours or a placebo solution of dextrose, 5%, infused at a rate
of 0.5 μg/kg/min for 4 hours. Participants were recumbent dur-
ing the infusions and blood pressure (BP), heart rate, blood oxy-
gen saturation, and electrocardiogram results were continu-
ously monitored during the course of the infusion.
Outcomes
The primary outcome measures examined were the PANSS
total, positive, and negative scores with SNP compared with
placebo across each 2-week phase. The secondary outcome
evaluated the safety and tolerability of SNP compared with pla-
cebo as measured by BP and heart rate, as well as the SAFTEE
and Abnormal Involuntary Movement Scale. Other outcomes
examined included cognitive changes as measured by the Mea-
surement and Treatment Research to Improve Cognition in
Schizophrenia Consensus Cognitive Battery and life skills as
measured by the University of California San Diego Perfor-
mance-based Skills Assessment Brief.
Statistical Analysis
The primary outcome regarding improvement in symptoms as
measured by the PANSS total, positive, and negative scales was
tested using the Tamura and Huang17 approach to SPCD for con-
tinuous data, where effect estimates from the 2 phases were
weighted (using a weighted z test) to compare differences be-
tween the SNP and placebo groups. The primary outcome
analysis was performed for all participants in the SNP and pla-
cebo groups, and then in distinct treatment subgroups (cloza-
pine vs no clozapine treatment, and more severe vs less se-
vere negative symptoms). The secondary outcome regarding
safety and tolerability as measured by the SAFTEE, BP, and
heart rate was examined at baseline, 7 hours after each infu-
sion, and after the final infusion. A modified intent-to-treat
analysis was used (ie, only including participants who at least
started the infusion), and per the SPCD design, only placebo
nonresponders were included in the phase 2 analyses, whereas
all participants from phase 1 were included.
We planned to randomize a sample size of 60 partici-
pants to ensure that at least 48 participants completed the
study, based on power calculations indicating that 60 partici-
pants needed to be randomized to obtain at least 81% power
to detect a weighted mean difference of 10 points in PANSS total
scores (9 points in phase 1 and 11 points in phase 2, with SD of
14) between the SNP group and placebo group with a type I er-
ror rate of 0.05. This calculation was based on a 20% attrition
rate by the fourth week and 30% placebo response at the end
of phase 1. The RCT logic calculator18 was used for this sample
size calculation.
Results
A total of 60 participants were randomized, and 52 participants
(12 women and 40 men) received the first infusion and were in-
cluded in the phase 1 analyses. Baseline clinical and demograph-
ic characteristics are summarized in Table 1. Briefly, in the SNP
and SNP group, the mean (SD) age was 47.1 (10.5) years, 10 of
18 (55.5%) were white, 6 (33.3%) were black, 1 (5.6%) was Asian,
and 1 participant’s race was identified as “other.” In the placebo
and SNP group, the mean (SD) age was 45.9 (12.3) years, 9 of 16
(56.3%) were white, 5 (31.3%) were black, and 2 (12.5%) were
Asian. In the placebo and placebo group, the mean (SD) age was
40.4 (11.0) years, 6 of 18 (33.3%) were white, 11 (61.1%) were
black, and 1 (5.6%) was Asian. Participants had a baseline mean
PANSS-total score of 81.0 (SNP and SNP group, 83.6; placebo and
SNP group, 77.6; and placebo and placebo group, 81.7), which
clinically corresponds to between moderately and markedly ill.19
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Fifty participants (96%) completed phase 1; 2 participants
terminated the study early. Of these 50 participants, 32
were included in the phase 2 outcome analyses as placebo
nonresponders. Per the SPCD design, the 18 participants
randomized to the SNP and SNP group were excluded from
phase 2 analyses, and there were no placebo responders
(ie, >20% reduction on the PANSS-total) to exclude from
phase 2. However, 2 participants withdrew prior to receiv-
ing the second infusion, and thus were excluded from phase
2 analyses. Of the 32 participants who entered phase 2, 30
(94%) completed phase 2. Participant information is
detailed in Figure 1.
Primary Outcome: PANSS Scores
There were no significant differences between the SNP and
placebo groups for change in PANSS-total (weighted
β = −1.04; z = −0.59; P = .57), PANSS-positive (weighted
β = −0.62; z = −0.93; P = .35), or PANSS-negative (weighted
β = −0.12; z = −0.19; P = .85) scores (Figure 2 and Table 2).
When stratified by treatment status at study entry, there
were no significant differences between the SNP and placebo
groups for PANSS-total, PANSS-positive, PANSS-negative, or
PANSS-general scores in either the clozapine-treated or the
non–clozapine-treated groups (eTable 1 in Supplement 2).
When stratified by severity of PANSS-negative scores, there
were no significant differences between the SNP and placebo
groups for PANSS-total, PANSS-positive, PANSS-negative, or
PANSS-general scores (eTable 2 in Supplement 2). The base-
line mean (SD) PANSS-negative score was 25 (3).
Secondary Outcome: Safety and Tolerability
There were no statistically significant differences in mean
SAFTEE scores between groups at baseline, 7 hours after the
first infusion, 7 hours after the second infusion, and at the
final follow-up visit, either as a main effect (F2,47 = 0.68; P = .51)
or an interaction effect over time (F8,47 = 1.64; P = .14). There
were significant differences over time (F4,47 = 7.59; P < .001),
where baseline 1 (ie, day 0), or pre-infusion SAFTEE scores,
were greater than scores at the 4 subsequent assessments (visit
1 vs baseline, t47 = 3.62; P < .001; visit 2 vs baseline, t47 = 4.00;
P < .001; visit 3 vs baseline, t47 = 5.47; P < .001; and visit 4 vs
baseline, t47 = 3.40; P < .001). The most frequently reported
symptoms at the moderate or severe level on the SAFTEE
are listed in eTable 3 in Supplement 2.
During both the first and second infusions, systolic and dia-
stolic BP were significantly lower in the SNP groups com-
pared with the placebo groups. After the infusions, BP re-
turned to normal (Figure 3), but on average during the 2-hour
follow-up period, BP remained detectably different for dia-
stolic BP (both infusions) and, for the first infusion, for sys-
tolic BP. We also observed pre-infusion differences for dia-
stolic BP (both infusions) and systolic BP (the first infusion
only), but with greater uncertainty around these estimates,
given that these estimates were based on only 2 observations
per participant. For heart rate, although it was numerically
different during both infusions (Figure 3), we did not find
statistically significant differences before, during, or after the
infusions.
There were no serious adverse events. One participant in
the SNP group developed asymptomatic hypotension (which
resolved) during the first infusion and withdrew from the study.
Another participant in the SNP group became hypotensive
during the second infusion and withdrew from the study.
There were no differences between groups on the Abnor-
mal Involuntary Movement Scale total score as measured at
baseline, 7 hours after the first infusion, 7 hours after the sec-
ond infusion, and at the final follow-up visit, either as a main
effect (F2,49 = 0.69; P = .51) or an interaction effect over time
(F8,49 = 1.18; P = .33). There were also no statistically signifi-
cant differences over time (F4,49 = 2.43; P = .06).
Among cognitive measures, there were no significant dif-
ferences in Measurement and Treatment Research to Improve
Cognition in Schizophrenia total change scores between the SNP
and placebo groups (weighted β = 1.11; z = −0.98; P = .34). There
were no statistically significant differences between the SNP and
placebo groups for the University of California San Diego Per-
formance-based Skills Assessment Brief total score (weighted
β = 1.11; z = −0.98; P = .34).
Table 1. Baseline Clinical and Demographic Characteristics
Characteristic
SNP and SNP
(n = 18)
Placebo and SNP
(n = 16)
Placebo and Placebo
(n = 18)
Demographics
Age, mean (SD), y 47.1 (10.5) 45.9 (12.3) 40.4 (11.0)
Female sex, No. (%) 4 (22.2) 4 (25.0) 4 (22.2)
Hispanic ethnicity, No. (%) 1 (5.6) 1 (6.3) 2 (11.1)
Race, No. (%)
White 10 (55.6) 9 (56.3) 6 (33.3)
Black 6 (33.3) 5 (31.3) 11 (61.1)
Asian 1 (5.6) 2 (12.5) 1 (5.6)
Other 1 (5.6) 0 0
Clinical Severity at Phase 1 Baseline (Visit 3)
PANSS score, mean (SD)
Total 83.6 (10.0) 77.6 (8.8) 81.7 (8.8)
Positive 24.9 (3.5) 22.3 (3.4) 22.6 (3.1)
Negative 20.9 (5.5) 20.3 (5.0) 21.4 (4.6)
Abbreviations: PANSS, Positive and
Negative Syndrome scale;
SNP, sodium nitroprusside.
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Discussion
In this multicenter, randomized clinical trial of adjunctive in-
travenous SNP, we identified no evidence of efficacy for out-
patients with schizophrenia who had previously failed to
achieve resolution of psychotic symptoms after at least 1 trial
of an antipsychotic medication. Neither primary nor second-
ary measures, including results of cognitive testing, demon-
strated symptomatic improvement. Overall, SNP was rela-
tively well tolerated.
These results contrast with those of the original positive
placebo-controlled trial by Hallak et al6 of SNP infusion in in-
dividuals with schizophrenia. In that single-site study of 20
inpatients, a 4-hour infusion of SNP at 0.5 μg/kg/min resulted
in a significant decrease in psychotic symptoms, as measured
by the Brief Psychiatric Rating Scale. A follow-up placebo-
controlled study of 20 patients demonstrated improvement
in impairments in cognitive function in patients with
schizophrenia.8 There are some key differences between our
study and the initial study by Hallak et al.6 In contrast to the
initial study by Hallak et al,6 which included 20 inpatients at 1
site, our study included 52 outpatients at 4 sites, making the
present results more generalizable and providing sufficient
power to detect differences between groups. Another differ-
ence between the 2 studies is the age of the patients: those in
Figure 1. CONSORT Flow Diagram
90 Patients consented
60 Patients deemed eligible by site
52 Patients included in phase 1 analyses
32 Patients included in phase 2 analyses
30 Patients not eligible
8 Patients did not receive first infusion
3 Withdrew
3 Had positive drug test results
2 Had abnormal vital signs
2 Patients did not have data at the end of phase 1
1 Had headache prior to infusion
1 Withdrew during infusion
20 Patients not valid for SPCD phase 2
18 Received SNP during phase 1
2 Withdrew prior to infusion
2 Patients did not have data at the end of phase 2
1 Had positive drug test results
1 Withdrew during infusion
18 Patients in group 1 (placebo and
placebo)
18 Patients completed
19 Patients in group 2 (placebo and
SNP)
12 Patients completed
7 Patients withdrew
23 Patients in group 3 (SNP and SNP)
16 Patients completed
7 Patients withdrew
18 Patients in group 1 (placebo and
placebo)
18 Patients completed
14 Patients in group 2 (placebo and
SNP)
12 Patients completed
2 Patients withdrew
16 Patients in group 2 (placebo and
SNP)
14 Patients completed
2 Patients withdrew
18 Patients in group 3 (SNP and SNP)
18 Patients completed
18 Patients in group 1 (placebo and
placebo)
18 Patients completed
60 Patients randomized
SNP indicates sodium nitroprusside;
and SPCD, sequential parallel
comparison design.
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our study are significantly older (SNP and SNP group: mean age,
47.1 years; SNP and placebo group: mean age, 45.9 years; and
placebo and placebo group: mean age, 40.4 years) than those
in the previous study (SNP group, 25.5 years; and placebo group,
25.6 years). Our results are similar to those of 2 subsequent stud-
ies that failed to show any benefit of intravenous SNP either in
reducing psychotic symptoms or in improving cognition.9,20
Stone et al9 found no improvement in spatial working memory
performance among patients with schizophrenia; like our study,
that study also consisted of a significantly older population,
which presumes a longer illness course. Another randomized,
double-blind placebo-control study of 42 individuals with
schizophrenia did not demonstrate any improvement in scores
on the PANSS or Weschler Adult Intelligence Scale after a 4-hour
intravenous SNP infusion, and also included a population with
longer duration of illness.20 The patients in the study by
Hallak et al6 were younger and likely earlier in the course of
illness; we cannot exclude the possibility that SNP could be
more effective for those with recent-onset psychosis. More-
over, as Maia-de-Oliveira and colleagues21 note, the study by
Stone et al9 included 7 cannabis users and 12 cigarette smok-
ers; both substances may affect the effectiveness of SNP. Al-
though we did not include cannabis users in our study, we did
include cigarette smokers (20 total), as there is a high preva-
lence of cigarette use among individuals with schizophrenia. We
also note in our study, as in the study by Stone et al9 but not in
the study by Hallak et al,6 there was a reduction in BP in the SNP
group, but not in the placebo group. This decrease in BP may
be owing to the older mean age of the participants; SNP may be
better tolerated in a younger population.
Similar to the studies by Stone et al9 and Wang et al,20 our
patient population had less severe negative symptoms than the
population in the study by Hallak et al.6 Sodium nitroprus-
side may be most effective in decreasing severe negative symp-
toms; this effectiveness may be owing in part to its actions as
an NMDA receptor modulator.22
In addition to the aforementioned randomized trials,
1 open-label study examining intravenous SNP treatment in
2 patients with clozapine-refractory (“ultra-treatment resis-
tant”) schizophrenia demonstrated significant improvement
of both positive and negative symptoms within 1 hour after
infusion.23 Conversely, we did not detect any differences in
PANSS scores between the SNP and placebo groups within our
treatment-resistant (clozapine-treated) population. Finally, we
used the PANSS-positive subscale to examine positive symp-
toms, differing from the initial study by Hallak et al6 in which
the Brief Psychiatric Rating Scale was used. Participants in our
study had a baseline mean PANSS-total score of 81.0 (SNP and
SNP group, 83.6; placebo and SNP group, 77.6; and placebo and
placebo group, 81.7), which clinically corresponds to be-
tween moderately and markedly ill.19 In the study by Hallak
et al,6 participants had a Brief Psychiatric Rating Scale base-
line score of approximately 22 (maximum score, 72), suggest-
ing a less globally ill population. As such, we also cannot
Figure 2. Change in Positive and Negative Syndrome Scale (PANSS) Scores for Phases 1 and 2
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Table 2. PANSS Scores (Total, Positive, and Negative) for Phases 1 and 2
SPCD Phase
Total Score, Mean (SD) Positive Subscale Score, Mean (SD) Negative Subscale Score, Mean (SD)
SNP Placebo SNP Placebo SNP Placebo
Phase 1 (n = 52)
Baseline 83.6 (10.0) 79.8 (8.9) 24.9 (3.5) 22.5 (3.2) 20.9 (5.5) 20.9 (4.8)
End 77.6 (12.2) 76.7 (11.0) 23.1 (4.6) 21.3 (3.6) 19.1 (4.7) 19.8 (5.1)
Change −6.0 (11.3) −2.5 (7.1) −1.8 (1.9) −0.8 (2.8) −1.9 (4.2) −1.0 (2.8)
Phase 2 (n = 32)
Baseline 74.0 (12.0) 78.8 (10.1) 20.7 (3.6) 21.8 (3.6) 18.5 (5.8) 20.8 (4.4)
End 71.8 (10.6) 74.7 (9.0) 21.3 (4.6) 22.4 (3.5) 18.1 (6.2) 19.8 (4.7)
Change −1.8 (8.2) −4.2 (6.4) 0.5 (3.8) 0.6 (2.2) −0.2 (0.9) −0.9 (3.0)
Abbreviations: PANSS, Positive and Negative Syndrome scale; SNP, sodium nitroprusside; SPCD, sequential parallel comparison design.
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Figure 3. Mean Blood Pressure and Heart Rate per Treatment Group for Each Infusion
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A, Mean systolic blood pressure for infusion 1. B, Mean systolic blood pressure for infusion 2. C, Mean diastolic blood pressure for infusion 1. D, Mean diastolic blood
pressure for infusion 2. E, Mean heart rate for infusion 1. F, Mean heart rate for infusion 2. During phase 1 (ie, infusion 1), 18 patients received sodium nitroprusside
(SNP) and 34 received placebo. During phase 2 (ie, infusion 2), 14 patients received SNP and 18 received placebo. Reference lines denote start and end of infusion.
Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia Original Investigation Research
jamapsychiatry.com (Reprinted) JAMA Psychiatry July 2019 Volume 76, Number 7 697
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 09/16/2019
exclude the possibility that SNP treatment could be more ef-
fective in treating less severe positive psychotic symptoms, al-
though this seems unlikely. We also consider the possibility
that SNP may be more effective not as an adjunctive treat-
ment, but as a single agent (ie, in patients not taking anti-
psychotic medications).
The exact mechanisms through which SNP could
decrease psychotic symptoms is not fully understood. So-
dium nitroprusside, which in clinical practice is used as an
antihypertensive agent, is converted to NO, resulting in vas-
cular smooth muscle relaxation and vasodilation. The NO may
act to increase cerebral perfusion to regions that have de-
creased areas of blood flow in patients with schizophrenia, per-
haps exerting an antipsychotic effect.24 It has also been pos-
tulated that the NO acts a neural modulator; SNP releases
NO, activating soluble guanylate cyclase, producing cyclic gua-
nosine monophosphate.25 As mentioned, activation of the
NMDA receptor also produces intracellular NO release through
activation of nNOS.7 The NMDA-nNOS-cyclic guanosine mono-
phosphate pathway is involved in long-term potentiation and
neuroplasticity, mediated partially by cyclic guanosine mono-
phosphate phosphorylating cAMP response element-binding
protein and protein kinase B. Nitric oxide is a signaling mol-
ecule that is also downstream from the NMDA receptor; there
is evidence that hypofunction of the NMDA receptor plays a
role in the pathogenesis of schizophrenia.26 Finally, in vitro
studies of neurons derived from patients with schizophrenia
provide evidence that NO production is decreased, suggest-
ing that NO is also decreased in brains of living patients.27 Con-
versely, overproduction of NO has also been associated with
neurotoxic effects and may play a role in some neurodegen-
erative disorders.28,29 Thus, there may be a critical balance of
NO that must be maintained, suggesting that any benefit of in-
terventions such as SNP could be dose specific.
Limitations
We note several important limitations in interpreting our
results. As mentioned, our participants were on average
older and likely to have experienced multiple episodes of
psychosis, so our results are not perfectly comparable with
the original results of Hallak et al.6 We used intravenous
SNP only at 1 dose and 1 duration of treatment, and there-
fore cannot investigate dose dependence of effects (eg, if
older individuals with a longer illness course require a
higher dose and longer treatment duration). A further limi-
tation is that we did not exclude cigarette smokers from our
study; nicotine in cigarettes can interfere with NO, poten-
tially diminishing the efficacy of SNP.30 Finally, we did not
use a precision-based medicine approach to stratify groups;
this method could potentially be used in future studies to
identify SNP responders.
Conclusions
Antipsychotic-treated patients with schizophrenia with some
evidence of treatment resistance did not show significant
improvement in psychotic symptoms or cognition after an
infusion of SNP across any of the measured outcomes. As
with any treatment, particular subgroups may respond differ-
ently; if further studies of NO donors are pursued, they might
focus on a younger, nonsmoking population earlier in the
course of illness, with alternate dosing and duration of drug
delivery.
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